External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00365872|
Recruitment Status : Completed
First Posted : August 18, 2006
Results First Posted : January 6, 2014
Last Update Posted : March 23, 2017
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Soft Tissue Sarcoma||Biological: Dendritic Cell (DC) Injections Procedure: Radiation therapy Procedure: Complete Resection - Surgery for tumor removal||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Combination of External Beam Radiation With Intratumoral Injection of Dendritic Cells as Neo-adjuvant Treatment of High-risk Soft Tissue Sarcoma Patients|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
Experimental: EBRT + DC Injection + Resection
Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
Biological: Dendritic Cell (DC) Injections
Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery
Procedure: Radiation therapy
Radiation was delivered 5 days per week (Monday-Friday).
Procedure: Complete Resection - Surgery for tumor removal
Tumors were surgically resected 3-6 weeks after the completion of EBRT.
- Overall Response Rate (ORR) [ Time Frame: Up to 3 years ]Immune responses in patients treated with EBRT and DCs: Transient immune response = response detected at only one time point; Robust immune response = response detected at least at two time points. An individual patient was considered a responder to tumor cell lysates (TCL) or survivin if at any time point the response in the interferon gamma (IFN-γ) enzyme-linked immunospot (ELISPOT) assay was higher than 30 spots per 2 X 10^5 cells and in the proliferation assay higher than 3,000 counts per minute (CPM) and the response in IFN-γ ELISPOT or proliferation assays to TCL or Ad-surv was more than 2 standard deviations (SD) higher than the response to the corresponding control lysate or Ad-c at the same time point and 2 SD higher than the response to the same stimuli before start of the treatment.
- Occurrence of Significant (>/= Grade 2) Toxicity [ Time Frame: Up to 3 years ]Toxicity assessment during combination external beam radiation therapy (EBRT)/DC neoadjuvant treatment. Toxicity was assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria.
- Occurrence of Postoperative Wound Complications [ Time Frame: Up to 3 years ]Postoperative wound complications were defined using NCI Common Toxicity Criteria (CTC).
- Participants With No Evidence of Disease at Follow-up [ Time Frame: 3 years ]Participants who had no evidence of the disease for at least one year after the start of the treatment (time of follow-up); for at least 2 years, and for at least 3 years.
- Number of Participants With Increase in Level of Radioactivity at Excision Per Cohort [ Time Frame: Up to 3 years ]To identify the nodes to be excised, an injection with Indium 111 (radio active dye) labeled dendritic cells (of vaccine #4) was performed 1 to 3 days prior to surgery. Patients were evenly divided to be assigned to one of three cohorts: Cohort 1, 1 day before surgery; Cohort 2, 2 days before surgery; Cohort 3, 3 days before surgery. Vaccine #4 was labeled in order to evaluate how long dendritic cells need to travel to regional draining lymphatics. Tumor resection was not delayed by this.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Intermediate or high grade sarcoma as determined by pathology review
- Musculoskeletal tumor in extremities, trunk or chest wall.
- Primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter.
- Clinical Stage T2N0M0 (AJCC 6th edition)
- Patient is not a candidate for neoadjuvant chemotherapy.
- Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.
- No steroid therapy within 4 weeks of first dendritic cell administration.
- No coagulation disorder.
- Patient's written informed consent.
- No contraindication to resection.
Adequate organ function (measured within a week of beginning treatment).
- White blood count (WBC) > 3,000/mm to the third power and absolute neutrophil count (ANC) >1500/mm to the third power
- Platelets > 100,000/mm to the third power
- Hematocrit > 25%
- Bilirubin < 2.0 mg/dL
- Creatinine < 2.0 mg/dL, or creatinine clearance > 60 mL/min
- Radiation Oncologist must confirm that a 2-3 cm strip of skin can be spared from radiation.
- Retroperitoneal location.
- Gastrointestinal stromal tumor (GIST).
- Demonstrated metastatic disease.
- Prior radiation therapy if the current tumor is locally recurrent after prior resection.
- Concurrent treatment with any anticancer agent other than radiation as dictated by the protocol.
- Bleeding disorder.
- H.I.V. infection or other primary immunodeficiency disorder.
- Ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate).
- Any serious ongoing infection.
- Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment).
- ECOG performance status of 2, 3 or 4.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00365872
|United States, Florida|
|H. Lee Moffitt Cancer Center & Research Institute|
|Tampa, Florida, United States, 33612|
|Principal Investigator:||Scott Antonia, M.D.||H. Lee Moffitt Cancer Center and Research Institute|
|Responsible Party:||H. Lee Moffitt Cancer Center and Research Institute|
|Other Study ID Numbers:||
|First Posted:||August 18, 2006 Key Record Dates|
|Results First Posted:||January 6, 2014|
|Last Update Posted:||March 23, 2017|
|Last Verified:||June 2013|
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type